LISTING OF CLAIMS

The listing of claims will replace all prior versions, and listings of claims in the application:

1. (Currently Amended) A compound selected from Formula Ia, Ib, ~~Ic,~~ and Id ~~and Ie~~:


Ia


Ib


Ic


Id


Ie

in which:

n is selected from 0, 1 and 2; ~~m is selected from 0, 1, 2 and 3;~~

W is selected from $-NR_4-$, $-S-$, $-O-$, $-S(O)-$ and $-S(O)_2-$; wherein R_4 is selected from hydrogen and C_{1-6}alkyl;

R_1 is selected from C_{6-10}aryl-C_{0-4}alkyl, C_{5-10}heteroaryl-C_{0-4}alkyl, C_{3-12}cycloalkyl-C_{0-4}alkyl and C_{3-8}heterocycloalkyl-C_{0-4}alkyl; wherein any arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl of R_1 is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, C_{6-10}aryl, C_{5-10}heteroaryl, C_{3-12}cycloalkyl, C_{3-8}heterocycloalkyl, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, $-XNR_5R_5$, $-XNR_5XNR_5R_5$, $-XNR_5XOR_5$, $-XOR_5$, $-XSR_5$, $-XS(O)R_5$, $-XS(O)_2R_5$, $-XC(O)NR_5R_5$, $-XOXR_6$ and $-XC(O)R_6$; wherein X is a bond or C_{1-6}alkylene; R_5 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl-C_{0-4}alkyl; and R_6 is selected from C_{3-8}heterocycloalkyl-C_{0-4}alkyl and C_{5-10}heteroaryl-C_{0-4}alkyl optionally substituted by 1 to 3 radicals selected from C_{1-6}alkyl and $-C(O)OH$; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent of R_1 is further optionally substituted by 1 to 5 radicals independently selected from C_{1-6}alkyl and C_{1-6}alkoxy;

R_2 is selected from C_{6-10}aryl-C_{0-4}alkyl, C_{5-10}heteroaryl-C_{0-4}alkyl, and C_{3-12}cycloalkyl-C_{0-4}alkyl ~~and C_{3-8}heterocycloalkyl-C_{0-4}alkyl~~; wherein any arylalkyl, heteroarylalkyl, or cycloalkylalkyl ~~or heterocycloalkylalkyl~~ of R_2 is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, C_{1-6}alkyl, C_{1-6}alkenyl, C_{1-6}alkynyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, halo-substituted-C_{1-6}alkoxy, C_{3-8}heteroarylC_{0-4}alkyl, $-XNR_5R_5$, $-XOR_5$, $-XSR_5$, $-XS(O)R_5$, $-XS(O)_2R_5$, $-XSNR_5R_5$, $-XS(O)NR_5R_5$, $-XS(O)_2NR_5R_5$, $-XC(O)OR_5$, $-XOC(O)R_5$, $-XC(O)R_5$, $-XC(O)NR_5XNR_5R_5$, $-XC(O)NR_5R_5$, $-XC(O)NR_5XC(O)OR_5$, $-XC(O)NR_5XNR_5C(O)R_5$, $-XC(O)NR_5XNR_5C(O)OR_5$, $-XC(O)NR_5XOR_5$, $-XC(O)N(XOR_5)_2$, $-XNR_5C(O)R_5$, $-XC(O)NR_5R_6$, $-XC(O)R_6$, $-XR_7$, $-XC(O)R_7$, $-XR_6$ and $-XC(O)NR_5XR_7$; wherein X is a bond or C_{1-6}alkylene; and R_5 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl-C_{0-4}alkyl; R_6 is selected from C_{3-8}heterocycloalkyl-C_{0-4}alkyl and C_{5-10}heteroaryl-C_{0-4}alkyl optionally substituted by 1 to 3 radicals selected from C_{1-6}alkyl and –C(O)OH; and R_7 is selected from halo and cyano;

R_3 is selected from halo, hydroxy, $-XSR_5$, $-XS(O)R_5$, $-XS(O)_2R_5$, $-XC(O)R_5$ and $-XC(O)OR_5$; wherein X is a bond or C_{1-6}alkylene; and R_5 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl-C_{0-4}alkyl; and the pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs thereof.

2. (Original) The compound of claim 1 in which:

W is selected from $-NR_4-$ and –O–; wherein R_4 is selected from hydrogen and C_{1-6}alkyl;

R_1 is selected from C_{6-10}aryl-C_{0-4}alkyl and C_{5-10}heteroaryl-C_{0-4}alkyl; wherein any arylalkyl and heteroarylalkyl of R_1 is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, C_{5-10}heteroaryl, C_{1-6}alkyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, $-XNR_5R_5$, $-XOR_5$, $-XSR_5$, $-XNR_5XNR_5R_5$, $-XNR_5XOR_5$, $-XC(O)NR_5R_5$, $-XOXR_6$ and $-XC(O)R_6$; wherein X is a bond or C_{1-6}alkylene; R_5 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl-C_{0-4}alkyl; and R_6 is selected from C_{3-8}heterocycloalkyl-C_{0-4}alkyl and C_{5-10}heteroaryl-C_{0-4}alkyl optionally substituted by 1 to 3 radicals selected from C_{1-6}alkyl and –C(O)OH; wherein any heteroaryl substituent of R_1 is further optionally substituted by 1 to 5 C_{1-6}alkyl radicals;

R_2 is selected from C_{6-10}aryl-C_{0-4}alkyl and C_{5-10}heteroaryl-C_{0-4}alkyl; wherein any arylalkyl or heteroarylalkyl of R_2 is optionally substituted by 1 to 3 radicals independently

selected from halo, nitro, cyano, C_{1-6}alkyl, C_{1-6}alkenyl, C_{1-6}alkoxy, halo-substituted-C_{1-6}alkyl, C_{3-8}heteroarylC_{0-4}alkyl, $-XNR_5R_5$, $-XOR_5$, $-XSR_5$, $-XS(O)_2NR_5R_5$, $-XC(O)OR_5$, $-XOC(O)R_5$, $-XC(O)NR_5XNR_5R_5$, $-XC(O)NR_5XC(O)OR_5$, $-XC(O)NR_5XNR_5C(O)R_5$, $-XC(O)NR_5XNR_5C(O)OR_5$, $-XC(O)NR_5XOR_5$, $-XC(O)N(XOR_5)_2$, $-XNR_5C(O)R_5$, $-XC(O)NR_5R_6$, $-XC(O)R_6$, $-XR_7$, $-XR_6$ and $-XC(O)NR_5XR_7$; wherein X is a bond or C_{1-6}alkylene; and R_5 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl-C_{0-4}alkyl; R_6 is selected from C_{3-8}heterocycloalkyl-C_{0-4}alkyl and C_{5-10}heteroaryl-C_{0-4}alkyl optionally substituted by 1 to 3 radicals selected from C_{1-6}alkyl and –C(O)OH; and R_7 is cyano; and

R_3 is selected from halo, hydroxy, $-XC(O)R_5$ and $-XC(O)OR_5$; wherein X is a bond or C_{1-6}alkylene; and R_5 is selected from hydrogen, C_{1-6}alkyl and C_{3-12}cycloalkyl-C_{0-4}alkyl.

3. (Original) The compound of claim 1 in which W is selected from –NH– and –O–; and R_1 is selected from phenyl, benzyl, 5,6,7,8-tetrahydro-naphthalenyl, benzo[1,3]dioxolyl, 1H-indazol-7-yl, indan-4-yl and 1H-indolyl; wherein any arylalkyl and heteroarylalkyl of R_1 is optionally substituted by 1 to 3 radicals independently selected from methoxy, methyl, amino, halo, hydroxymethyl, hydroxy, quinoxalinyl, ethyl, pyridinyl, methoxy-phenyl, piperazinyl-carbonyl, ethyl-(2-hydroxy-ethyl)-amino 2-(4-methyl-piperazin-1-yl)-ethoxy, formamyl, isopropyl, methyl-sulfanyl, tri-fluoro-methyl, ethoxy, 3-isopropylamino-propylamino, dimethyl-amino, morpholino, cyclopropyl-methoxy, butoxy, cycloheptyl-oxy and 1,4,5,7-tetramethyl-pyrrolo[3,4-d]pyridazinyl.

4. (Original) The compound of claim 1 in which R_2 is selected from pyridinyl, phenyl, thiazolyl, pyridinyl-methyl, pyridinyl-ethyl, thiophenyl, benzyl, quinolinyl, 7-oxo-5,6,7,8-tetrahydro-naphthalenyl, naphthyl and pyrimidinyl; wherein any arylalkyl or heteroarylalkyl of R_2 is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, methyl, propyl-sulfamoyl, methyl-sulfamoyl, methoxy, methyl-carboxy, 2-dimethylamino-ethyl-formamyl, carboxy, amino, cyano-ethyl, cyano-methyl, ethenyl, tri-fluoro-methyl, hydroxy-methyl, ethyl, methyl-sulfanyl, butyl, isobutyl, carboxy-methyl-formamidyl, 1-carboxy-ethyl-formamidyl, carboxy-ethyl, amino-ethyl-formamidyl, amino-propyl-formamidyl, dimethyl-amino-ethyl-formamidyl, dimethyl-amino-propyl-formamidyl, dimethyl-amino-butyl-formamidyl, methyl-formamidyl, ethyl-formamidyl, ethyl-formamidyl-methyl, 2-(2-

dimethylamino-ethylcarbamoyl)-ethyl, 2-(2-dimethylamino-formamidyl)-ethyl, 2-(amino-ethyl-formamidyl)-ethyl, 2-(amino-propyl-formamidyl)-ethyl, 2-(propyl-formamidyl)-ethyl, amino-propyl-formamidyl-methyl, 2-(methyl-amino-carbamoyl)-ethyl, 2-(ethyl-amino-carbamoyl)-ethyl, morpholino-ethyl-formamidyl, morpholino-carbonyl-methyl, amino-ethyl-formamidyl-methyl, cyclobutyl-formamidyl, methyl-formamidyl-methyl, dimethyl-formamidyl-methyl, hydroxy-ethyl-formamidyl-methyl, hydroxy-propyl-formamidyl-methyl, N,N-bis-(3-hydroxy-propyl)-formamidyl, cyclopentyl-formamidyl, isobutyl-formamidyl, isobutyl-formamidyl-methyl, cyclopentyl-formamidyl-methyl, cyano-ethyl-formamidyl, cyano-methyl-formamidyl, pyrrolidinyl-ethyl-formamidyl, 2-(isobutyl-formamidyl)-ethyl, 1H-tetrazolyl, 2-(1H-tetrazol-5-yl)-ethyl, 2-(1H-tetrazol-5-yl)-methyl, 2-(1-methyl-1H-tetrazol-5-yl)-methyl, acetyl-amino, cyclopropyl-formamidyl-methyl, hydroxy-ethyl-formamidyl, hydroxy-propyl-formamidyl, propyl-formamidyl-methyl, ethoxy-propyl-formamidyl, acetyl-amino-ethyl-formamidyl, 1-methyl-piperidin-4-yl-formamidyl, morpholino-carbonyl-ethyl, methoxy-carbonyl-methyl, methoxy-carbonyl-ethyl-formamidyl, methoxy-carbonyl-ethyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl, 4-amino-cyclohexyl-formamidyl, 4-amino-cyclohexyl-formamidyl-methyl, acetyl-amino-ethyl-formamidyl-methyl, ethoxy-propyl-formamidyl-methyl, methoxy-carbonyl-ethyl, 1-formyl-pyrrolidin-2-yl-carboxylic acid, (1-carboxy-3-methyl-butyl)-formamidyl, 2-(methoxy-carbonyl-methyl-formamidyl)-ethyl, 1-carboxy-(2,2-dimethyl-propyl)-formamidyl, 3-tert-butoxycarbonyl-amino-propyl-formamidyl, acetoxy-methyl and 1-carboxy-ethyl-formamidyl.

5. (Currently Amended) The compound of claim 1 in which n is 0 or 1; ~~m is 0 or 1;~~ and R_3 is selected from halo, hydroxy, –C(O)OH and –C(O)OCH_3.

6. (Original) The compound of claim 1 of Formula Ig:



Ig

in which R_2 is selected from pyridinyl, phenyl, thiazolyl, pyridinyl-methyl, pyridinyl-ethyl, thiophenyl, benzyl, quinolinyl, 7-oxo-5,6,7,8-tetrahydro-naphthalenyl, naphthyl and pyrimidinyl; wherein any arylalkyl or heteroarylalkyl of R_2 is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, methyl, propyl-sulfamoyl, methyl-sulfamoyl, methoxy, methyl-carboxy, 2-dimethylamino-ethyl-formamyl, carboxy, amino, cyano-ethyl, cyano-methyl, ethenyl, tri-fluoro-methyl, hydroxy-methyl, ethyl, methyl-sulfanyl, butyl, isobutyl, carboxy-methyl-formamidyl, 1-carboxy-ethyl-formamidyl, carboxy-ethyl, amino-ethyl-formamidyl, amino-propyl-formamidyl, dimethyl-amino-ethyl-formamidyl, dimethyl-amino-propyl-formamidyl, dimethyl-amino-butyl-formamidyl, methyl-formamidyl, ethyl-formamidyl, ethyl-formamidyl-methyl, 2-(2-dimethylamino-ethylcarbamoyl)-ethyl, 2-(2-dimethylamino-formamidyl)-ethyl, 2-(amino-ethyl-formamidyl)-ethyl, 2-(amino-propyl-formamidyl)-ethyl, 2-(propyl-formamidyl)-ethyl, amino-propyl-formamidyl-methyl, 2-(methyl-amino-carbamoyl)-ethyl, 2-(ethyl-amino-carbamoyl)-ethyl, morpholino-ethyl-formamidyl, morpholino-carbonyl-methyl, amino-ethyl-formamidyl-methyl, cyclobutyl-formamidyl, methyl-formamidyl-methyl, dimethyl-formamidyl-methyl, hydroxy-ethyl-formamidyl-methyl, hydroxy-propyl-formamidyl-methyl, N,N-bis-(3-hydroxy-propyl)-formamidyl, cyclopentyl-formamidyl, isobutyl-formamidyl, isobutyl-formamidyl-methyl, cyclopentyl-formamidyl-methyl, cyano-ethyl-formamidyl, cyano-methyl-formamidyl, pyrrolidinyl-ethyl-formamidyl, 2-(isobutyl-formamidyl)-ethyl, 1H-tetrazolyl, 2-(1H-tetrazol-5-yl)-ethyl, 2-(1H-tetrazol-5-yl)-methyl, 2-(1-methyl-1H-tetrazol-5-yl)-methyl, acetyl-amino, cyclopropyl-formamidyl-methyl, hydroxy-ethyl-formamidyl, hydroxy-propyl-formamidyl, propyl-formamidyl-methyl, ethoxy-propyl-formamidyl, acetyl-amino-ethyl-formamidyl, 1-methyl-piperidin-4-yl-formamidyl, morpholino-carbonyl-ethyl, methoxy-carbonyl-methyl, methoxy-carbonyl-ethyl-formamidyl, methoxy-carbonyl-ethyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl, 4-amino-cyclohexyl-formamidyl, 4-amino-cyclohexyl-formamidyl-methyl, acetyl-amino-ethyl-formamidyl-methyl, ethoxy-propyl-formamidyl-methyl, methoxy-carbonyl-ethyl, 1-formyl-pyrrolidin-2-yl-carboxylic acid, (1-carboxy-3-methyl-butyl)-formamidyl, 2-(methoxy-carbonyl-methyl-formamidyl)-ethyl, 1-carboxy-(2,2-dimethyl-propyl)-formamidyl, 3-tert-butoxycarbonyl-amino-propyl-formamidyl, acetoxy-methyl and 1-carboxy-ethyl-formamidyl.

7. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.

8. (Original) A method for treating a disease in an animal in which inhibition of kinase activity can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Claim 1.

9. (Original) The method of claim 7 in which the kinase is selected from FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and c-Met.

10. (Canceled) The use of a compound of claim 1 in the manufacture of a medicament for treating a disease in an animal in which the kinase activity of FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and/or c-Met contributes to the pathology and/or symptomology of the disease.

11. (New) The compound of claim 1 selected from:







	
	
	
	
	

	
	
	
	
	

	
	
	
	
	

	
	
	
	
	

	
	
	
	
	

	
	
	
	
	



























12. (New) A compound selected from:



;



; and



.